Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. (1st November 2016)

• Record Type: Journal Article
• Authors: Calandre, Elena P.; Rico-Villademoros, Fernando; Slim, Mahmoud
• Is Part Of: Expert review of neurotherapeutics. Volume 16:Number 11(2016)
• Page Start: 1263
• Page End: 1277
• Publication Date: 2016-11-01
• Subjects: Gabapentin -- pregabalin -- mirogabalin -- alpha2delta ligands -- mechanism of action -- pharmacokinetics -- drug interactions -- adverse reactions -- clinical indications; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1080/14737175.2016.1202764
• Languages: English
• ISSNs: 1473-7175

Abstract

ABSTRACT: Introduction : The first two alpha2 delta ligands – gabapentin (GBP) and pregabalin (PGB) – were initially synthesized as antiepileptics; however, they were later also found to be useful for the treatment of additional conditions. Areas covered : Relevant publications describing potential underlying mechanisms, clinical pharmacokinetics/pharmacokinetics, and clinical efficacy and safety of these drugs in various disease conditions were searched in PubMed and Scopus and included in this review. Expert commentary : GBP and PGB are effective for the treatment neuropathic pain, fibromyalgia and epilepsy; in addition, they may be useful for the reduction of postoperative pain. PGB is also effective for the treatment of generalized anxiety disorder and GBP for the treatment of restless legs syndrome. GBP may be considered a treatment option for pain associated with Guillain-Barré Syndrome and phantom limb and for the management of uremic pruritus. Mirogabalin (MGB), recently developed, is being investigated for the treatment of peripheral neuropathic pain and fibromyalgia, showing promising results in patients with diabetic peripheral neuropathy. Their most frequent adverse reactions are of neuropsychiatric nature and include fatigue, dizziness, sedation, somnolence, and ataxia; peripheral edema and weight gain are also frequently described. Pharmacokinetic interactions are scarce; however, pharmacodynamic interactions have been described in association with drugs with CNS-depressant effects.